Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study
Zhe Cao, Jiangdong Qiu, Wenhao Luo, Juan Li, Hao Chen, Yueze Liu, Shengmian Li, Fei Li, Yinmo Yang, Yuejuan Cheng, Taiping Zhang, Huadan Xue, Chunmei Bai, Yupei Zhao · 2026
Read Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study by Zhe Cao, Jiangdong Qiu, Wenhao Luo, Juan Li, Hao Chen, Yueze Liu, Shengmian Li, Fei Li, Yinmo Yang, Yuejuan Cheng, Taiping Zhang, Huadan Xue, Chunmei Bai, Yupei Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13284206.txt.
Description
Two-drug induction chemo bought time and sometimes surgery for advanced pancreas cancer in a 2026 phase 2 trial by Zhe Cao and colleagues. Locally advanced disease carries poor outlook and few treatment choices. Nab-paclitaxel plus S-1 served as first treatment across four China centers.
Sixty untreated patients enrolled between April 2019 and March 2023. Nearly half completed the full induction course of up to eight cycles. About a fifth later had tumor removal surgery after shrinking. Six-month freedom from progression cleared seventy percent in the trial. Serious side effects hit over half, mainly low white cell counts. No treatment deaths occurred.
Catalog record
| CREATOR | Zhe Cao, Jiangdong Qiu, Wenhao Luo, Juan Li, Hao Chen, Yueze Liu, Shengmian Li, Fei Li, Yinmo Yang, Yuejuan Cheng, Taiping Zhang, Huadan Xue, Chunmei Bai, Yupei Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42124 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |